Spyre Therapeutics Raises $463M, Secures $1.2B Cash Runway, Accelerates Q3 2026 RA Readout
Spyre Therapeutics reported positive Phase 2 SKYLINE Part A induction data for SPY001, announced over-enrollment and accelerated the rheumatoid arthritis sub-study readout to the third quarter of 2026, and affirmed six proof-of-concept readouts across SKYLINE and SKYWAY in 2026. The company raised $463 million in an underwritten stock offering, boosting pro forma cash to $1.2 billion to fund operations into the second half of 2029.
1. Q1 Financing Boost
Spyre closed an underwritten public offering of common stock, generating $463 million gross proceeds. Pro forma cash, cash equivalents and marketable securities total approximately $1.2 billion as of March 31, 2026, with an expected operational runway into the second half of 2029.
2. SPY001 Phase 2 SKYLINE Update
Part A of the Phase 2 SKYLINE trial of SPY001 in moderately to severely active inflammatory bowel disease reported positive topline induction data with a safety profile consistent with the α4β7 class. The company also announced over-enrollment in the rheumatoid arthritis sub-study of the Phase 2 SKYWAY basket trial and accelerated the RA readout to the third quarter of 2026.
3. Upcoming Proof-of-Concept Milestones
Spyre remains on track for six proof-of-concept readouts across its SKYLINE and SKYWAY platforms in 2026, including mid-2026 topline data for SPY002, third quarter results for SPY003 in IBD, and proof-of-concept data for rheumatoid arthritis in Q3 2026, with PsA and axSpA readouts expected in the fourth quarter.